Work

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells

Year: 2015

Type: conference-abstract

Abstract: Meeting abstracts Several monoclonal antibodies (MAbs) with demonstrated clinical anti-cancer activities have been engineered as fully human IgG1 entities to also encompass their potential to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) of human tumor cells. Avelumab (MSB0010718C,

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p254

Authors: Lauren Lepone, Renee Donahue, Italia Grenga, Caroline Jochems, Kwong-Yok Tsang, Simon Metenou, Jacob Richards, Christopher R Heery, Ravi Madan, James L Gulley, Jeffrey Schlom

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2192829665

Cites:

Cited by:

Related to: 10